Ocugen, Inc. (OCGN)
NASDAQ: OCGN · IEX Real-Time Price · USD
1.660
+0.025 (1.53%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Ocugen Revenue
Ocugen had revenue of $7.05M in the twelve months ending March 31, 2024, with 140.53% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.01M with 128.89% year-over-year growth. In the year 2023, Ocugen had annual revenue of $6.04M with 142.60% growth.
Revenue (ttm)
$7.05M
Revenue Growth
+140.53%
P/S Ratio
60.60
Revenue / Employee
$108,462
Employees
65
Market Cap
427.21M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.04M | 3.55M | 142.60% |
Dec 31, 2022 | 2.49M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 43.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 26.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sonida Senior Living | 260.69M |
Voyager Therapeutics | 119.04M |
EyePoint Pharmaceuticals | 50.02M |
Taysha Gene Therapies | 14.16M |
Nano-X Imaging | 10.01M |
Altimmune | 410.00K |
OCGN News
- 4 weeks ago - Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease - GlobeNewsWire
- 4 weeks ago - Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication - GlobeNewsWire
- 5 weeks ago - OCGN DEADLINE TODAY: TOP RANKED ROSEN LAW FIRM Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm – OCGN - GlobeNewsWire
- 5 weeks ago - OCGN DEADLINE TODAY: ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action First Filed by the Firm – OCGN - Business Wire
- 5 weeks ago - DEADLINE TODAY: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm - Business Wire
- 6 weeks ago - FINAL OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit! - Accesswire
- 6 weeks ago - SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. - OCGN - Accesswire
- 6 weeks ago - The Schall Law Firm Encourages Investors With Losses in Ocugen, Inc. to Touch Base With the Firm Before the June 10th Deadline - Accesswire